Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 11/20 | 0.43 |
| ▸ | MEN1 | O00255 | 9/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 8/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2957792 | 0.82 | ACHE (0.43) | KMT2AMEN1ACHENPC1MAPT | |
| SCHEMBL13198982 | 0.80 | MAPT (0.43) | KMT2AMEN1NPC1MAPTHTT | |
| SCHEMBL2957637 | 0.80 | KMT2A (0.45) | KMT2AMEN1ACHENPC1MAPT | |
| SCHEMBL13199017 | 0.77 | ROCK1 (0.42) | KMT2AMEN1NPC1MAPTHTT | |
| SCHEMBL2960046 | 0.76 | KMT2A (0.47) | KMT2AMEN1NPC1MAPTHTT | |
| SCHEMBL2959953 | 0.76 | KMT2A (0.44) | KMT2AMEN1ACHEMAPTHTT | |
| SCHEMBL2961641 | 0.75 | KMT2A (0.45) | KMT2AMEN1ACHENPC1MAPT | |
| SCHEMBL2961877 | 0.75 | KMT2A (0.45) | KMT2AMEN1ACHENPC1MAPT | |
| SCHEMBL2950908 | 0.75 | KMT2A (0.45) | KMT2AMEN1ACHENPC1MAPT | |
| SCHEMBL2961585 | 0.75 | ROCK1 (0.47) | KMT2AMEN1MAPTHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767681-B2 | 2-Carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-08-03 | — | — | US | claimed |
| EP-1771425-B1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2008-05-14 | — | — | EP | claimed |
| US-20070179126-A1 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-08-02 | — | — | US | claimed |
| US-7767681-B2 | 2-Carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-08-03 | — | — | US | disclosed |
| EP-1771425-B1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2008-05-14 | — | — | EP | disclosed |
| US-20070179126-A1 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179126-A1 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | UGT2B7, PKD2, CYP2C19 | KMT2A 1446/4885MEN1 990/4885ACHE 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.